Frovatriptan

CLINICAL USE

Acute relief of migraine

DOSE IN NORMAL RENAL FUNCTION

2.5 mg; a second dose can be taken if required after at least 2 hoursMaximum daily dose is 5 mg

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :243.3

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :15

%Excreted unchanged in urine &nbsp &nbsp : 10–32

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :3–4.2

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :26/ Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Likely dialysability. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Likely dialysability. Dose as in normal renal function

HDF/high flux &nbsp :Likely dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Likely dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antidepressants: blood levels of frovatriptan increased 27–49% by fluvoxamine – avoid concomitant use; possibly increased serotonergic effects with duloxetine and SSRIs; increased serotonergic effects with St John’s wort – avoid concomitant use

Ergot alkaloids: increased risk of vasospasm

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

Tags: post-by-auto-php